Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

66,404 76,093 Unaudited consolidated statement of cash flows ThromboGenics Unaudited consolidated statement of cash flow For the period ended 6 months 6 months Jan 2009 Jan 2008 In '000 Euro, except per share amounts - June 2009 - June 2008 According to IFRS OPERATING ACTIVITIES {Loss} profit for the period (4,663) 18,028 Financial expenses 179 190 Financial income (1,034) (1,022) Depreciation of property, plant and equipment 224 195 Depreciation of intangible assets 1 - Costs of share-based payments 249 304 Cash flows before modification of the working capital (5,044) 1,695 (Increase) / decrease in trade and other receivables including tax receivables (85) (30,703) Increase / (decrease) in short-term liabilities 508 4,884 Net cash flow from operating activities (4,621) (8,124) INVESTING ACTIVITIES Retirement of fixed assets (6) (2) Investments 22,809 (32) Interest received and similar income 894 838 Acquisition of intangible assets (345) (95) Acquisition of property, plant and equipment (4,908) - Net cash (used for) / generated by investment activities 18,444 709 FINANCING ACTIVITIES Income from share issues 3,025
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... to announce that the final design specifications of ... Prototypes for industrial and regulatory testing will now ... CE mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... announced,today that it has licensed its proprietary reverse ... and construction of new,vaccine strains to produce inactivated ... is a method by which viruses,such as influenza ... prospective,pandemic influenza vaccines, reverse genetics can be a ...
... Corporation today,announced that it has been awarded five federal grants and ... -- Two Phase II SBIR grants totaling $2.4 million to further ... platform and alternative nanoparticle technologies, focused primarily ... [Principal ...
... Drug Development, Dosing Determination, and Pharmacogenetic Testing ... Test Commercialization and Broadens Geographic Reach ... ... Data, Inc.,(Nasdaq: CLDA ) announced today that it has acquired ...
Cached Biology Technology:MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production 2Mirus Bio Awarded Grants & Contracts of Over $5 Million 2Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 2Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 3Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 4Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 5Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 6
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/30/2015)... Calif. , July 30, 2015 ... services for gene function analysis and biomarker discovery, ... RNA (sgRNA) Knockout Library targeting all human protein ... and permanently "knock out" a gene,s function. Cellecta,s ... a high throughput screening tool so that researchers ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... a new front in the war against flu, researchers ... of a novel compound that confers broad protection against ... work, reported online this week (Oct. 4, 2006) in ... peptide -- a small protein molecule -- that effectively ...
... few square meters in size, where fluid is released ... which are active areas of fluid seepage, are other ... give rise to some of the most extreme and ... planet. , Extensive fields of hydrocarbon-rich gas seepage, ...
... this morning where I put my car keys last ... Scientists at the Max Planck Institute for Medical Research ... consolidated. Their new study offers the hitherto strongest proof ... short term memory area, and the cerebral cortex during ...
Cached Biology News:New drug blocks influenza, including bird flu virus 2New drug blocks influenza, including bird flu virus 3Life in the extreme 2Learning during sleep? 2
Request Info...
... fast and efficient microplate stacker ... capacity and reliable design allow for ... time than typical stackers. Its ... for a seamless and trouble-free installation ...
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
Biology Products: